- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01541306
C-Type Natriuretic Peptide and Achondroplasia
Study Overview
Status
Conditions
Detailed Description
Achondroplasia is the most common form of dwarfism and is characterized by short limbs with the thighs and upper arms being the most affected. Achondroplasia is also associated with a narrowing of the foramen magnum and spinal stenosis. Hypochondroplasia is a related, but less severe form of dwarfism that does not have the neurologic problems. Achondroplasia and hypochondroplasia are caused by mutations in the fibroblast growth factor receptor-3 (FGFR-3) gene that causes constitutive activation of the receptor. FGFR-3 signals primarily through the MAP kinase pathway, which is overactivated in growth plate chondrocytes in achondroplasia. C-type natriuretic peptide (CNP) is a hormone that is produced and acts in the growth plate as a potent positive regulator of linear growth. CNP signals through natriuretic peptide receptor-B (NPR-B), generating cGMP. Studies in mice show that activation of the MAP kinase pathway inhibits signaling through NPR-B. Hence the achondroplasia phenotype may be due in part to inhibition of CNP signaling. Conversely, CNP intracellular signaling inhibits the MAP kinase pathway and CNP analogs are being studied as a potential specific therapy for achondroplasia. The objective of this project is to define the state of the CNP system in children and adults with achondroplasia or hypochondroplasia. Our hypotheses are 1) blood levels of CNP and its aminoterminal propeptide (NTproCNP) are elevated and blood levels of cGMP are reduced in children with achondroplasia or hypochondroplasia, due to inhibition of NPR-B; 2) CNP and NTproCNP levels are normal in adults with achondroplasia and hypochondroplasia, due to their lack of growth plate cartilage; and 3) as in healthy children, NTproCNP levels predict height velocity in children with achondroplasia or hypochondroplasia. These hypotheses will be addressed with two specific aims. Specific aim 1 is to determine plasma levels of CNP, NTproCNP, and cGMP in children and adults with achondroplasia or hypochondroplasia. Specific aim 2 is to determine if NTproCNP levels correlate with height velocity in children with achondroplasia or hypochondroplasia.
The study is an observational, cross-sectional/partially longitudinal study of children and adults with achondroplasia or hypochondroplasia. Children will be seen as part of routine clinic visits. Children seen more than once during the study period will provide longitudinal data. Adult subjects with achondroplasia or hypochondroplasia will be studied a single time. Data collected will include anthropometrics, information on neurologic complications of achondroplasia, and blood levels of CNP, NTproCNP, and cGMP. We anticipate 100 subjects will be recruited, with about 20 being studied as many as three times during the course of the study.
By studying the potential role of the CNP system in achondroplasia and hypochondroplasia, not only will we provide further insight into the pathophysiology of these common syndromes, we will also provide greater insight into the regulation of normal linear growth.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfred I. DuPont Hospital for Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- a diagnosis of achondroplasia or hypochondroplasia
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
achondroplasia or hypochondroplasia
Children or adults with achondroplasia or hypochondroplasia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NTproCNP level in plasma
Time Frame: one time point
|
Aminoterminal propeptide of CNP (NTproCNP) is measured in plasma by RIA and compared to an existing sex- and age- based reference range.
|
one time point
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CNP level in plasma
Time Frame: one time point
|
C-type natriuretic peptide is measured in plasma by RIA and compared to an existing sex- and age- based reference range.
|
one time point
|
cGMP level in plasma
Time Frame: one time point
|
Cyclic GMP levels are measured in plasma by RIA and compared to existing age- and sex- matched control samples.
|
one time point
|
Correlation between NTproCNP level and height velocity in children
Time Frame: Every six months over a period of a minumum of six months to a maximum of 2 years
|
NTproCNP levels at baseline will be correlated with hieght velocity determined at subsequent visits.
Measurements for determination of height velocity will be at least 6 months apart, but no more than 2 years apart.
For subjects with multiple subsequent visits, the visit closest to 1 year after the baseline visit will be used for height velocity determination.
|
Every six months over a period of a minumum of six months to a maximum of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Olney, MD, Nemours Children's Clinic
- Principal Investigator: Michael Bober, MD, PhD, Alfred I. DuPont Hospital for Children
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Nemours FL IRB 302926
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Achondroplasia
-
GeneScience Pharmaceuticals Co., Ltd.Tongji Hospital; Shengjing Hospital; Shandong Provincial Hospital; Children's Hospital... and other collaboratorsRecruiting
-
Johns Hopkins UniversityUniversity of Wisconsin, Madison; University of Texas; BioMarin Pharmaceutical; Alfred I. duPont Hospital for Children and other collaboratorsEnrolling by invitationAchondroplasia
-
PfizerTerminatedAchondroplasiaBelgium, United States, Japan, Australia, Portugal, Denmark, Italy, Spain
-
PfizerTerminatedAchondroplasiaUnited States, Australia, Belgium, Denmark, Italy, Portugal, Spain
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, Japan, United Kingdom
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaAustralia, United Kingdom
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, United Kingdom, Japan, Spain, Turkey
-
BioMarin PharmaceuticalPicnicHealthRecruitingAchondroplasiaUnited States
-
Ascendis Pharma Growth Disorders A/SActive, not recruitingAchondroplasiaUnited States, Denmark, Ireland, New Zealand, Australia, Canada, Spain
-
Ascendis Pharma A/SActive, not recruitingAchondroplasiaUnited States, Australia, Austria, Denmark, Germany, Ireland, New Zealand, Portugal